Golüke Nienke M S, Schoffelmeer Marit A, De Jonghe Annemarieke, Emmelot-Vonk Mariëlle H, De Jong Pim A, Koek Huiberdina L
University Medical Center Utrecht, Department of Geriatrics, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
Tergooi Hospitals, Department of Geriatrics, Rijksstraatweg 1, 1261 AN Blaricum, the Netherlands.
Bone Rep. 2022 Jun 18;17:101599. doi: 10.1016/j.bonr.2022.101599. eCollection 2022 Dec.
To clarify the role of mediators of ectopic mineralization as biomarkers for arterial calcifications.
MEDLINE and Embase were searched for relevant literature, until January 4th 2022. The investigated biomarkers were: calcium, phosphate, parathyroid hormone, vitamin D, pyrophosphate, osteoprotegerin, receptor activator of nuclear factor-kappa B ligand (RANKL), fibroblast growth factor-23 (FGF-23), Klotho, osteopontin, osteocalcin, Matrix Gla protein (MGP) and its inactive forms and vitamin K. Studies solely performed in patients with kidney insufficiency or diabetes mellitus were excluded.
After screening of 8985 articles, a total of 129 articles were included in this systematic review. For all biomarkers included in this review, the results were variable and more than half of the studies for each specific biomarker had a non-significant result. Also, the overall quality of the included studies was low, partly as a result of the mostly cross-sectional study designs. The largest body of evidence is available for phosphate, osteopontin and FGF-23, as a little over half of the studies showed a significant, positive association. Firm statements for these biomarkers cannot be drawn, as the number of studies was limited and hampered by residual confounding or had non-significant results. The associations of the other mediators of ectopic mineralization with arterial calcifications were not clear.
Associations between biomarkers of ectopic mineralization and arterial calcification are variable in the published literature. Future longitudinal studies differentiating medial and intimal calcification could add to the knowledge of biomarkers and mechanisms of arterial calcifications.
阐明异位矿化介质作为动脉钙化生物标志物的作用。
检索MEDLINE和Embase数据库以获取相关文献,检索截至2022年1月4日。所研究的生物标志物包括:钙、磷、甲状旁腺激素、维生素D、焦磷酸盐、骨保护素、核因子κB受体活化因子配体(RANKL)、成纤维细胞生长因子23(FGF-23)、klotho蛋白、骨桥蛋白、骨钙素、基质Gla蛋白(MGP)及其无活性形式以及维生素K。仅在肾功能不全或糖尿病患者中进行的研究被排除。
在筛选了8985篇文章后,本系统评价共纳入129篇文章。对于本评价中纳入的所有生物标志物,结果各不相同,每种特定生物标志物的研究中超过一半结果无统计学意义。此外,纳入研究的总体质量较低,部分原因是大多采用横断面研究设计。关于磷、骨桥蛋白和FGF-23的证据最多,略超过一半的研究显示出显著的正相关。由于研究数量有限且受残余混杂因素影响或结果无统计学意义,因此无法对这些生物标志物做出肯定的陈述。其他异位矿化介质与动脉钙化之间的关联尚不清楚。
已发表文献中异位矿化生物标志物与动脉钙化之间的关联各不相同。未来区分中膜钙化和内膜钙化的纵向研究可能会增加对动脉钙化生物标志物和机制的认识。